Natural products: an evolving role in future drug discovery
The therapeutic areas of infectious diseases and oncology have benefited from abundant
scaffold diversity in natural products, able to interact with many specific targets within the cell …
scaffold diversity in natural products, able to interact with many specific targets within the cell …
Reward, addiction, withdrawal to nicotine
M De Biasi, JA Dani - Annual review of neuroscience, 2011 - annualreviews.org
Nicotine is the principal addictive component that drives continued tobacco use despite
users' knowledge of the harmful consequences. The initiation of addiction involves the …
users' knowledge of the harmful consequences. The initiation of addiction involves the …
Human disease-drug network based on genomic expression profiles
G Hu, P Agarwal - PloS one, 2009 - journals.plos.org
Background Drug repositioning offers the possibility of faster development times and
reduced risks in drug discovery. With the rapid development of high-throughput technologies …
reduced risks in drug discovery. With the rapid development of high-throughput technologies …
Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice
Strategies for assisting smoking cessation include behavioural counselling to enhance
motivation and to support attempts to quit and pharmacological intervention to reduce …
motivation and to support attempts to quit and pharmacological intervention to reduce …
Catalytic mechanism of cytochrome P450 for 5′-hydroxylation of nicotine: fundamental reaction pathways and stereoselectivity
A series of computational methods were used to study how cytochrome P450 2A6 (CYP2A6)
interacts with (S)-(−)-nicotine, demonstrating that the dominant molecular species of (S)-(−) …
interacts with (S)-(−)-nicotine, demonstrating that the dominant molecular species of (S)-(−) …
Nicotine vaccines to assist with smoking cessation: current status of research
T Raupach, PHJ Hoogsteder, CP van Schayck - Drugs, 2012 - Springer
Tobacco smoking causes cardiovascular, respiratory and malignant disease, and stopping
smoking is among the key medical interventions to lower the worldwide burden of these …
smoking is among the key medical interventions to lower the worldwide burden of these …
Natural products in drug discovery: impacts and opportunities—an assessment
G Brahmachari - … natural products: opportunities and challenges in …, 2012 - World Scientific
Nature stands as an inexhaustible source of novel chemotypes and pharmacophores, and
has been a source of medicinal agents for thousands of years, and an impressive number of …
has been a source of medicinal agents for thousands of years, and an impressive number of …
Molecular actions of smoking cessation drugs at α4β2 nicotinic receptors defined in crystal structures of a homologous binding protein
B Billen, R Spurny, M Brams… - Proceedings of the …, 2012 - National Acad Sciences
Partial agonists of the α4β2 nicotinic acetylcholine receptor (nAChR), such as varenicline,
are therapeutically used in smoking cessation treatment. These drugs derive their …
are therapeutically used in smoking cessation treatment. These drugs derive their …
New pharmacological agents to aid smoking cessation and tobacco harm reduction: what has been investigated, and what is in the pipeline?
A wide range of support is available to help smokers to quit and to aid attempts at harm
reduction, including three first-line smoking cessation medications: nicotine replacement …
reduction, including three first-line smoking cessation medications: nicotine replacement …
Tobacco dependence and withdrawal: science base, challenges and opportunities for pharmacotherapy
Several pharmacotherapies for tobacco dependence and withdrawal have been approved
by the Food and Drug Administration to aid smoking cessation. These medicines double to …
by the Food and Drug Administration to aid smoking cessation. These medicines double to …